<DOC>
	<DOCNO>NCT00648778</DOCNO>
	<brief_summary>The objective study investigate bioequivalence Mylan loxapine succinate 25 mg capsule Watson Loxitane 25 mg capsule follow single , oral 25 mg ( 1 x 25 mg ) dose administration fasting condition .</brief_summary>
	<brief_title>Fasting Study Loxapine Succinate Capsules 25 mg LoxitaneÂ® Capsules 25 mg</brief_title>
	<detailed_description />
	<mesh_term>Loxapine</mesh_term>
	<criteria>1 . Age : 18 year old . 2 . Sex : Male nonpregnant , nonlactating female . Women childbearing potential must negative serum ( Beta HCG ) pregnancy test perform within 14 day prior start study even prior dose administration . An additional serum ( Beta HCG ) pregnancy test perform upon completion study . b . Women childbearing potential must practice abstinence use acceptable form contraception throughout duration study . No hormonal contraceptive hormonal replacement therapy permit study . Acceptable form contraception include follow : 1 ) intrauterine device place least 3 month prior start study remain place study period , 2 ) barrier method contain use conjunction spermicidal agent , 3 ) surgical sterility ( tubal ligation , oophorectomy hysterectomy ) postmenopausal accompany document postmenopausal course least one year . c. During course study , study screen study exit include washout period , woman childbearing potential must use spermicide contain barrier method contraception addition current contraceptive device . This advice document informed consent form . 3 . Weight : At least 60 kg ( 132 lb ) man 48 kg ( 106 lb ) woman within 15 % Ideal Body Weight ( IBW ) , reference Table `` Desirable Weights Adults '' Metropolitan Life Insurance Company , 1999 ( See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS ) . 4 . All subject judge normal healthy prestudy medical evaluation ( physical examination , laboratory evaluation , 12lead ECG , hepatitis B hepatitis C test , HIV test , urine drug screen include amphetamine , barbiturate , benzodiazepine , cannabinoid , cocaine , opiates , phencyclidine , methadone ) perform within 14 day initial dose study medication . 1 . Institutionalized subject use . 2 . Social Habits : . Use tobacco product . b. Ingestion alcoholic , caffeine xanthinecontaining food beverage within 48 hour prior initial dose study medication . c. Ingestion vitamin within 48 hour prior initial dose study medication . d. Any recent , significant change dietary exercise habit . 3 . Medications : . Use medication within 14 day prior initial dose study medication . b . Use medication know alter hepatic enzyme activity within 28 day prior initial dose study medication . 4 . Diseases : . History significant chronic disease and/or hepatitis . b . History drug and/or alcohol abuse . 5 . Abnormal clinically significant laboratory test result : a. Clinically significant deviation Guide Clinically Relevant Abnormalities ( See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS ) . b. Abnormal clinically relevant ECG tracing . 6 . Donation loss significant volume blood plasma ( &gt; 450 mL ) within 28 day prior initial dose study medication . 7 . Subjects receive investigational drug within 30 day prior initial dose study medication . 8 . Allergy hypersensitivity Loxitane , inactive ingredient , related product . 9 . History difficulty swallow , gastrointestinal disease could affect drug absorption . 10 . Consumption grapefruit grapefruit containing product within 7 day drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>